Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference View Full Press Release Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS Travere Therapeutics Provides Corporate Update and 2026 Outlook